Status:
TERMINATED
Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
35+ years
Brief Summary
1. A prospective, non-interventional study, 125 patients with Diabetes Mellitus Type2 will be enrolled, who, while on metformin, have a sub-optimal glycemic control and who thus will receive additiona...
Eligibility Criteria
Inclusion
- Diabetes Mellitus Type 2 for \> 6 months on treatment with only metformin for \>4 weeks
- HbA1c value \>7.0 and therefore a sulfonylurea derivative is added
- Able to complete a series of questionnaires
Exclusion
- Concomitant treatment with an other antidiabetic than metformin and SU derivative
- Contraindications for the use of metformin or SU derivative
- Concomitant diseases which may affect the patient's ability to complete study
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01244646
Start Date
December 1 2010
End Date
August 1 2012
Last Update
December 6 2012
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alkmaar, Netherlands
2
Research Site
Edam, Netherlands
3
Research Site
Gorinchem, Netherlands
4
Research Site
Heerhugowaard, Netherlands